Emily Marden is counsel in Sidley’s Food and Drug Regulatory group. She has an expansive practice in which she addresses regulatory and strategic issues raised by emerging science in the food, agriculture and drug and biotechnology arenas. She has extensive experience with regulatory aspects of novel genetic technologies, including applications of gene therapy and genome editing in human therapeutic products, animal drugs, foods and agricultural crops. In addition, Emily has broad expertise with issues involving innovator and follow-on drug product exclusivities, complex drugs, biological products and biosimilars. With regard to agricultural crops, Emily extensive experience addressing issues involving sharing of genomics data and information. Emily has acted as in-house counsel to both a large pharmaceutical and a successful biotechnology company, where she advised on a range of regulatory and business law issues.
In addition to her regulatory practice, Emily directs research on genomics and innovation in agriculture and medicine at the University of British Columbia and teaches there in the Faculty of Law.
118A, Level 100